IOX1

Research use only, not for human use.

IOX1 is a potent, broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases.

IOX1 is a potent, broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases, with IC50 of <1 uM gainst the KDM3, KDM4 and KDM6, 5-25 uM against the KDM5 and KDM2/7; IOX1 is less potent against BBOX1 (IC50=196 uM); chelates to Fe(II) in the active site of 2OG oxygenases; suppresses the proliferation and migration of vascular smooth muscle cells induced by angiotensin II.

IOX1 (0-200 μM; 2 hours) inhibits the proliferation and migration of vascular smooth muscle cells (VSMCs) stimulated with angiotensin II (Ang II) in a concentration-dependent manner.IOX1 (200 μM; 24 hours) blocks the cell cycle progression of angiotensin II (Ang II)-VSMCs by increasing the percentage of cells in the G0/G1 phase.IOX1 (50-200 μM; 2 hours) attenuates cyclin D1 and upregulates p21 mRNA levels in a concentration-dependent.IOX1 (50-200 μM; 2 hours) mediates cyclin D1 and p21 expression by regaining H3K9me3. Cell Proliferation Assay Cell Line:Vascular smooth muscle cells (VSMCs) Concentration:50 μM, 100 μM, 200 μM Incubation Time:Pretreated 2 hours Result:Exhibited a decrease in proliferation and migration.Cell Cycle Analysis Cell Line:Vascular smooth muscle cells (VSMCs) Concentration:200 μM Incubation Time:24 hours Result:Slowed down the progression of the cell cycle from the G0/G1 to the S phase.RT-PCR Cell Line:Vascular smooth muscle cells (VSMCs) Concentration:50 μM, 100 μM, 200 μM Incubation Time:2 hours Result:Decreased cyclin D1 mRNA expression and increased p21 mRNA expression.RT-PCR Cell Line:Vascular smooth muscle cells (VSMCs) Concentration:50 μM, 100 μM, 200 μM Incubation Time:2 hours Result:Enhanced the total protein levels of H3K9me3.

IOX1 (5-c-8HQ) (oral gavage; 10-20 mg/kg; 12 days) inhibits tumor growth and attenuates the self-renewal of liver cancer stem-like cells (LCSCs) in vivo. Animal Model:Six-week-old male BALB/c nude mice Dosage:10 mg/kg, 20 mg/kg Administration:12 days Result:Did not result in obvious adverse effects on mice as demonstrated by no body weight reduction and no toxicity to the major organs after treatment.Inhibited LCSC orthotopic graft tumor growth.Significantly reduced the protein levels of EpCAM and Sox9 in LCSC orthotopic graft tumors nhibited LCSC orthotopic graft tumor growth.Decreased Ki67-positive tumor cells and markedly reduced the tumorsphere formation abilities of LCSCs in a dose-dependent manner.

IOX 1 | IOX-1

Chromatin/Epigenetic

Histone Demethylase

KDM2A|KDM3A|KDM4C|KDM4E|KDM6B

Cancer

——

5852-78-8

189.1675

C10H7NO3

>98% (HPLC)

DMSO: 24 mg/mL

O=C(C1=C2C=CC=NC2=C(O)C=C1)O

5-Quinolinecarboxylic acid, 8-hydroxy-

(-20℃)

With Ice Pack

≥ 2 years